ImmunityBio, Inc. (IBRX)

Name: ImmunityBio, Inc. (IBRX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001326110 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, ImmunityBio, Inc. reported revenue of $113.29M. Revenue grew 668.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $165.79M.

Key ratios (year ended 2025-12-31)

-226.0%

Operating margin

-310.2%

Net margin

668.3%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-14

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$165.79M	$113.29M	$14.74M	$622.0K	$240.0K	$934.0K	$605.0K	$2.20M	$47.0K	$45.0K	$44.0K
Cost of Revenue	$1.09M	$753.0K	$0	$0	$0	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	n/a	n/a	$190.14M	$232.37M	$248.15M	$195.96M	$139.51M	$112.00M	$55.72M	$42.04M	$29.15M
Operating Income	-$251.80M	-$256.03M	-$344.18M	-$362.25M	-$351.30M	-$330.28M	-$220.88M	-$156.25M	-$98.39M	-$99.12M	-$124.50M
Depreciation & Amortization	$16.60M	$15.53M	$17.55M	$18.51M	$18.26M	$14.24M	$12.74M	$14.04M	$9.55M	$5.57M	$3.61M
EBITDA	-$235.20M	-$240.50M	-$326.63M	-$343.74M	-$333.04M	-$316.04M	-$208.14M	-$142.21M	-$88.83M	-$93.55M	-$120.89M
Net Income	-$992.36M	-$351.40M	-$413.56M	-$583.20M	-$416.57M	-$346.79M	-$221.85M	-$157.78M	-$96.23M	-$96.42M	-$120.81M
EPS (Diluted)	n/a	-$0.38	-$0.62	-$1.15	-$1.04	-$0.89	-$0.59	-$0.43	n/a	n/a	n/a
Total Assets	$628.50M	$501.90M	$382.93M	$504.45M	$362.36M	$468.91M	$221.38M	$143.12M	$181.95M	$250.44M	$317.50M
Total Liabilities	$1.67B	$1.00B	$871.06M	$1.09B	$812.18M	$712.82M	$339.87M	$22.44M	$35.94M	$31.60M	$24.08M
Shareholders' Equity	-$1.05B	-$500.47M	-$489.10M	-$586.99M	-$447.33M	-$242.17M	-$119.81M	$120.68M	$146.01M	$218.84M	$293.42M
Cash & Equivalents	$75.67M	$88.33M	$143.43M	$265.45M	$104.64M	$181.10M	$34.91M	$75.80M	$16.82M	$23.87M	$8.08M
Operating Cash Flow	-$281.14M	-$304.94M	-$391.24M	-$366.76M	-$337.51M	-$274.42M	-$171.72M	-$152.11M	-$63.38M	-$48.78M	-$38.59M
Capital Expenditures	$6.94M	$3.85M	$6.89M	$30.58M	$78.16M	$33.56M	$1.67M	$4.29M	$13.10M	$34.81M	$6.56M
Free Cash Flow	-$288.07M	-$308.78M	-$398.12M	-$397.34M	-$415.67M	-$307.98M	-$173.39M	-$156.40M	-$76.48M	-$83.59M	-$45.15M
Share Repurchases	n/a	n/a	n/a	n/a	n/a	$0	$0	$2.50M	$228.0K	$15.23M	$15.85M
Shares Outstanding	1.05B	1.01B	852.90M	670.87M	421.57M	397.83M	382.24M	98.46M	79.09M	79.02M	81.98M
Weighted Average Diluted Shares	n/a	919.86M	700.44M	508.64M	399.90M	389.23M	377.07M	366.32M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.38	-$0.59	-$1.15	-$1.04	-$0.89	-$0.59	-$0.43	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView